Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge

Vaccine

Volumn 33, Issue 17, 2015, Pages 2086-2095

  Sholukh, Anton M ^a,c,d   Watkins, Jennifer D ^c,d   Vyas, Hemant K ^a,c,d   Gupta, Sandeep ^e   Lakhashe, Samir K ^a,c,d   Thorat, Swati ^c,d   Zhou, Mingkui ^a   Hemashettar, Girish ^c   Bachler, Barbara C ^c   Forthal, Donald N ^e   Villinger, Francois ^f,g   Sattentau, Quentin J ^h   Weiss, Robin A ⁱ   Agatic, Gloria ^j   Corti, Davide ^j,k   Lanzavecchia, Antonio ^k,l   Heeney, Jonathan L ^m   Ruprecht, Ruth M ^a,b,c,d  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j Humabs BioMed SA ^*  (Switzerland)

^k INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^l ETH ZURICH   (Switzerland)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

(6 max); Complete protection; IgA; IgG; Passive immunization; Rhesus monkey; SHIV C mucosal challenge

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ERDOSTEINE; HGN 194 IMMUNOGLOBULIN A2 MONOCLONAL ANTIBODY; HGN 194 IMMUNOGLOBULIN G1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS RNA;

ALLELE; ANIMAL CELL; ANTIBODY COMBINING SITE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IC50; IMMUNE RESPONSE; IN VITRO STUDY; LIMIT OF DETECTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PASSIVE IMMUNIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSCYTOSIS; ANIMAL; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA; MUCOSAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; PATHOGENICITY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, MUCOSAL; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MACACA MULATTA; MUCOUS MEMBRANE; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES;

EID: 84925938609     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.02.020     Document Type: Article

References (48)

1. Rerks-Ngarm S. Pitisuttithum P. Nitayaphan S. Kaewkungwal J. Chiu J. Paris R. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
2. Haynes B.F. Gilbert P.B. McElrath M.J. Zolla-Pazner S. Tomaras G.D. Alam S.M. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
3. Bonsignori M. Pollara J. Moody M.A. Alpert M.D. Chen X. Hwang K.K. et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012, 86:11521-11532.
4. Tomaras G.D. Ferrari G. Shen X. Alam S.M. Liao H.X. Pollara J. et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 2013, 110:9019-9024.
5. Neutra M.R. Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
6. Ryan E.J. Daly L.M. Mills K.H. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 2001, 19:293-304.
7. Belyakov I.M. Hel Z. Kelsall B. Kuznetsov V.A. Ahlers J.D. Nacsa J. et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 2001, 7:1320-1326.
8. Kubota M. Miller C.J. Imaoka K. Kawabata S. Fujihashi K. McGhee J.R. et al. Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates. J Immunol 1997, 158:5321-5329.
9. Vajdy M. Singh M. Kazzaz J. Soenawan E. Ugozzoli M. Zhou F. et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retrovir 2004, 20:1269-1281.
10. Bomsel M. Tudor D. Drillet A.S. Alfsen A. Ganor Y. Roger M.G. et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269-280.
11. Lehner T. Wang Y. Cranage M. Bergmeier L.A. Mitchell E. Tao L. et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996, 2:767-775.
12. Corti D. Langedijk J.P. Hinz A. Seaman M.S. Vanzetta F. Fernandez-Rodriguez B.M. et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010, 5:e8805.
13. Watkins J.D. Sholukh A.M. Mukhtar M.M. Siddappa N.B. Lakhashe S.K. Kim M. et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 2013, 27:F13-F20.
14. Woof J.M. Russell M.W. Structure and function relationships in IgA. Mucosal Immunol 2011, 4:590-597.
15. Scinicariello F. Engleman C.N. Jayashankar L. McClure H.M. Attanasio R. Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology 2004, 111:66-74.
16. Zhou M. Ruprecht R.M. Are anti-HIV IgAs good guys or bad guys?. Retrovirology 2014, 11:109.
17. Siddappa N.B. Watkins J.D. Wassermann K.J. Song R. Wang W. Kramer V.G. et al. R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS ONE 2010, 5:e11689.
18. Cline A.N. Bess J.W. Piatak M. Lifson J.D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 2005, 34:303-312.
19. Hofmann-Lehmann R. Swenerton R.K. Liska V. Leutenegger C.M. Lutz H. McClure H.M. et al. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res Hum Retrovir 2000, 16:1247-1257.
20. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005, Chapter 12:Unit 12.1.
21. McLinden R.J. Labranche C.C. Chenine A.L. Polonis V.R. Eller M.A. Wieczorek L. et al. Detection of HIV-1 neutralizing antibodies in a human CD4(+)/CXCR4(+)/CCR5(+) T-lymphoblastoid cell assay system. PLoS ONE 2013, 8:e77756.
22. Sholukh A.M. Byrareddy S.N. Shanmuganathan V. Hemashettar G. Lakhashe S.K. Rasmussen R.A. et al. Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology 2014, 11:8.
23. Edmonds T.G. Ding H. Yuan X. Wei Q. Smith K.S. Conway J.A. et al. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010, 408:1-13.
24. Watkins J.D. Siddappa N.B. Lakhashe S.K. Humbert M. Sholukh A. Hemashettar G. et al. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS ONE 2011, 6:e18207.
25. Gupta S. Gach J.S. Becerra J.C. Phan T.B. Pudney J. Moldoveanu Z. et al. The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog 2013, 9:e1003776.
26. Patton D.L. Sweeney Y.C. Cummings P.K. Meyn L. Rabe L.K. Hillier S.L. Safety and efficacy evaluations for vaginal and rectal use of BufferGel in the macaque model. Sex Transm Dis 2004, 31:290-296.
27. Kararli T.T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995, 16:351-380.
28. Cavarelli M. Scarlatti G. HIV-1 infection: the role of the gastrointestinal tract. Am J Reprod Immunol 2014, 71:537-542.
29. Baggaley R.F. White R.G. Boily M.C. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010, 39:1048-1063.
30. Woof J.M. Mestecky J. Mucosal immunoglobulins. Immunol Rev 2005, 206:64-82.
31. Artenstein A.W. VanCott T.C. Sitz K.V. Robb M.L. Wagner K.F. Veit S.C. et al. Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical information. J Infect Dis 1997, 175:265-271.
32. Mestecky J. Jackson S. Moldoveanu Z. Nesbit L.R. Kulhavy R. Prince S.J. et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retrovir 2004, 20:972-988.
33. Raux M. Finkielsztejn L. Salmon-Ceron D. Bouchez H. Excler J.L. Dulioust E. et al. Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retrovir 1999, 15:1365-1376.
34. Wright P.F. Kozlowski P.A. Rybczyk G.K. Goepfert P. Staats H.F. VanCott T.C. et al. Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retrovir 2002, 18:1291-1300.
35. Belec L. Meillet D. Gaillard O. Prazuck T. Michel E. Ngondi Ekome J. et al. Decreased cervicovaginal production of both IgA1 and IgA2 subclasses in women with AIDS. Clin Exp Immunol 1995, 101:100-106.
36. Lu F.X. Predominate HIV1-specific IgG activity in various mucosal compartments of HIV1-infected individuals. Clin Immunol 2000, 97:59-68.
37. Schafer F. Kewenig S. Stolte N. Stahl-Hennig C. Stallmach A. Kaup F.J. et al. Lack of simian immunodeficiency virus (SIV) specific IgA response in the intestine of SIV infected rhesus macaques. Gut 2002, 50:608-614.
38. Israel Z.R. Marx P.A. Nonclassical mucosal antibodies predominate in genital secretions of HIV-1 infected chimpanzees. J Med Primatol 1995, 24:53-60.
39. Fiore J.R. Laddago V. Lepera A. La Grasta L. Di Stefano M. Saracino A. et al. Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. N Microbiol 2000, 23:85-92.
40. Qiao X. He B. Chiu A. Knowles D.M. Chadburn A. Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006, 7:302-310.
41. Rath T. Kuo T.T. Baker K. Qiao S.W. Kobayashi K. Yoshida M. et al. The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 2013, 33(Suppl. 1):S9-S17.
42. Shingai M. Donau O.K. Plishka R.J. Buckler-White A. Mascola J.R. Nabel G.J. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 2014, 211:2061-2074.
43. Johansen F.E. Kaetzel C.S. Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity. Mucosal Immunol 2011, 4:598-602.
44. Merrill W.W. Goodenberger D. Strober W. Matthay R.A. Naegel G.P. Reynolds H.Y. Free secretory component and other proteins in human lung lavage. Am Rev Respir Dis 1980, 122:156-161.
45. Sela-Culang I. Kunik V. Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol 2013, 4:302.
46. Tudor D. Yu H. Maupetit J. Drillet A.S. Bouceba T. Schwartz-Cornil I. et al. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A 2012, 109:12680-12685.
47. Rasmussen R.A. Siddappa N.B. Lakhashe S.K. Watkins J. Villinger F. Ibegbu C. et al. High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. AIDS 2012, 26:149-155.
48. Lakhashe S.K. Wang W. Siddappa N.B. Hemashettar G. Polacino P. Hu S.L. et al. Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS ONE 2011, 6:e22010.